HC-030031 is primarily used in research settings as a selective antagonist for the TRPA1 receptor, which is involved in pain sensation and inflammatory responses. It is widely utilized in studies to investigate the role of TRPA1 in various physiological and pathological conditions, such as chronic pain, neuropathic pain, and inflammatory diseases. Researchers employ HC-030031 to block TRPA1 channels, helping to understand their contribution to pain signaling and to explore potential therapeutic targets for pain management. Additionally, it is used in preclinical studies to evaluate the efficacy of TRPA1 inhibition in reducing hypersensitivity and inflammation in animal models. Its application extends to studying the mechanisms of sensory transduction and the development of novel analgesics.